TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05366387

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intrapulmonary percussive ventilation
Description: Intrapulmonary percussive ventilation is a non invasive ventilation technique where small boli or air are delivered, at adjustable frequency and pressure, to the upper airways though a mouthpiece. IPV is currently used in the clinic to aid with airway clearance in neuromuscular and airway diseases.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: delivery of 99mTc-DTPA aerosol
Description: A 99mTc-DTPA aerosol (500 MBq+/-20%, 3 ml volume) is generated with a jet nebuliser (MMAD 4 µm). The aerosol is inhaled by the study subject and lung deposition is imaged by SPECT

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: delivery of 99mTc-DTPA aerosol
Description: A 99mTc-DTPA aerosol (500 MBq+/-20%, 3 ml volume) is generated with a jet nebuliser (MMAD 4 µm). The aerosol is inhaled by the study subject and lung deposition is imaged by SPECT
Study: NCT05288543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG7236- Single ascending dose
Description: Subjects will receive IPG7236 tablets orally once on Day 1 in a fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG7236- Multiple ascending dose
Description: Subjects will receive IPG7236 tablets orally once daily for 10 days from Day1 to Day 10 in a fasted state

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part A)
Description: Subjects will receive IPG7236 tablets orally once on Day 1 (Part A) or once daily for 10 days from Day1 to Day 10 (Part B) in a fasted state
Study: NCT04795141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-035
Description: ABY-035 Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-035
Description: ABY-035 Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-035
Description: ABY-035 Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-035
Description: ABY-035 Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-035
Description: ABY-035 Solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline for injection
Study: NCT05591131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: genetic testing
Description: Undergo genetic testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study: NCT05308836

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: adipose-derived messenchymal stem cell
Description: Collaborative research program between Vinmec Research Institute of Stem Cell and Gene Technology with the National Yang-Ming University in Taiwan The adipose mesenchymal stem cell line (GXIPC1) was collected from healthy donors who have screened for infectious diseases and then multiplied in large numbers. These products were produced following the GMP laboratory system and approved by Taiwan FDA for preclinical and clinical trials with completed certificates
Study: NCT06330402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection
Description: 0.25 mL injection with hypertonic saline (7%) to the infrapatellar fat pad.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline injection
Description: Control injection with 0.25 mL isotonic saline (0.9%) to the infrapatellar fat pad.
Study: NCT06119724

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar enbloc resection of bladder tumor
Description: Enbloc retrival of bladder tumor entoto using cystoscopy using bipolar

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thulium laser enbloc resection of bladder tumor
Description: Enbloc retrival of bladder tumor entoto using cystoscopy using thulium laser
Study: NCT04924205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FM2 Knee Brace
Description: Participants in this group will use the FM2 Knee Brace for their post-TKA physical therapy.
Study: NCT05769374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cooperative versus competitive AVG play
Description: The duration of the study was 8 weeks and the frequency was 60 minutes three times a week. In the first two weeks, three games, Golf, Just Dance and Tennis, will be selected to experiment on easy and normal difficulty respectively. In the three weeks from week 3 to Week 5, Bowling, Shape Boxing and Table tennis will be selected for the experiment with easy, normal and difficult difficulties respectively. In the last three weeks, Rowing, Family ski and Baseball will be selected to carry out experiments with easy, ordinary and difficult difficulty respectively.Additionally,participants in control group did not participate in any AVG intervention and maintained their daily physical activity behaviors

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cooperative versus competitive AVG play
Description: The duration of the study was 8 weeks and the frequency was 60 minutes three times a week. In the first two weeks, three games, Golf, Just Dance and Tennis, will be selected to experiment on easy and normal difficulty respectively. In the three weeks from week 3 to Week 5, Bowling, Shape Boxing and Table tennis will be selected for the experiment with easy, normal and difficult difficulties respectively. In the last three weeks, Rowing, Family ski and Baseball will be selected to carry out experiments with easy, ordinary and difficult difficulty respectively.Additionally,participants in control group did not participate in any AVG intervention and maintained their daily physical activity behaviors

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cooperative versus competitive AVG play
Description: The duration of the study was 8 weeks and the frequency was 60 minutes three times a week. In the first two weeks, three games, Golf, Just Dance and Tennis, will be selected to experiment on easy and normal difficulty respectively. In the three weeks from week 3 to Week 5, Bowling, Shape Boxing and Table tennis will be selected for the experiment with easy, normal and difficult difficulties respectively. In the last three weeks, Rowing, Family ski and Baseball will be selected to carry out experiments with easy, ordinary and difficult difficulty respectively.Additionally,participants in control group did not participate in any AVG intervention and maintained their daily physical activity behaviors
Study: NCT06433401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional care training with brochures, posters and slide training materials
Description: Education at 3 and 6 months after the first interview
Study: NCT05600738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RNS/DBS activation
Description: This will be performed to study the EEG responses to DBS/RNS stimulation electrical pulses. The stimulation frequencies will be sequentially increased and each stimulation will last for 2 minutes.There will be a 1-2 minute wash out period after each trial.
Study: NCT06125054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: single dose of ketamine (0.71mg/kg bodyweight i.v. over 40 minutes)
Study: NCT05123716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Participants will be given 100 mg of MDMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Participants will be given 100 mg of MDMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo oral tablet
Description: Participants will be given a placebo capsule that will only contain lactose.
Study: NCT06125054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: single dose of ketamine (0.71mg/kg bodyweight i.v. over 40 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single dose of placebo (0.9% saline solution i.v. over 40 minutes)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose of placebo (0.9% saline solution i.v. over 40 minutes)
Study: NCT05123716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo oral tablet
Description: Participants will be given a placebo capsule that will only contain lactose.
Study: NCT06125054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: real-time fMRI neurofeedback training
Description: Real-time fMRI based neurofeedback over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on an experimental region. The training is repeated three times.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: real-time fMRI neurofeedback training
Description: Real-time fMRI based neurofeedback over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on an experimental region. The training is repeated three times.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sham real-time fMRI neurofeedback training
Description: Sham real-time fMRI neurofeedback training over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on a control region. The training is repeated three times.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: sham real-time fMRI neurofeedback training
Description: Sham real-time fMRI neurofeedback training over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on a control region. The training is repeated three times.
Study: NCT05569473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEST GROUP: VCMX + OFD, CONTROL GROUP : OFD ONLY
Description: A full-thickness mucoperiosteal flap will be raised, no bone recontouring would be performed, Thorough debridement of the surgical site would be performed. For the test group, VCMX would be placed according to the dimensions of the intrabony defect after open flap debridement (OFD). For the control group, OFD will be done and After this, flaps would be approximated and sutured at the original position with a monofilament suture material using interrupted sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEST GROUP: VCMX + OFD, CONTROL GROUP : OFD ONLY
Description: A full-thickness mucoperiosteal flap will be raised, no bone recontouring would be performed, Thorough debridement of the surgical site would be performed. For the test group, VCMX would be placed according to the dimensions of the intrabony defect after open flap debridement (OFD). For the control group, OFD will be done and After this, flaps would be approximated and sutured at the original position with a monofilament suture material using interrupted sutures.
Study: NCT05269732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioural Therapy (CBT)
Description: The 9-week group Cognitive Behavioural Therapy (CBT) intervention for Postpartum Depression (PPD) delivered via Zoom by two trained psychologists. This intervention was developed by Dr. Van Lieshout (Principal Investigator) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced each week. The first half of each session is devoted to core CBT content, including cognitive restructuring. The second half is devoted to group discussions co-led by participants on topics relevant to mothers with PPD (e.g., sleep, supports, role transitions). Homework is assigned at each session.
Study: NCT05587842

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Weightbearing management post operation
Description: Subjects will be instructed to be weightbearing, as tolerated, on their ankle starting at two weeks post operation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Weightbearing management post operation (Traditional)
Description: Subjects will be instructed to be non-weightbearing on their ankle until at least 6 weeks. After 6 weeks, the subject will be instructed to be weightbearing as tolerated.
Study: NCT06496581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PMSA-617
Description: Once every 6 weeks, 7400 MBq 177Lu-PMSA-617 will be administered for up to a total of 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: ADT, abiraterone and each ARSI (Apalutamide, Darolutamide, Enzalutamide) will be administrated according to the standard of care
Study: NCT05585762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: 75 mL chocolate flavored beverage containing 25 g of ketone ester. Half a bottle (12.5 g/day) will be consumed for the first 7 days and a complete bottle (25 g/day) will be consumed for the remaining 77 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-ketone placebo
Description: 75 mL chocolate flavored beverage containing 25 g of non-ketogenic fat. Half a bottle (12.5 g/day) will be consumed for the first 7 days and a complete bottle (25 g/day) will be consumed for the remaining 77 days.
Study: NCT06327113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CeFAZolin Injectable Solution
Description: One gram Cefazolin reconstituted in 100 mL 0.9% Sodium Chloride (normal saline)
Study: NCT05569655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Within 12 hours of admission, subjects were randomly assigned to two groups using the central randomization method. For subjects in group A, tolvaptan (15 mg/d) is added to standard therapy (furosemide:20-40mg/d). The treatment lasts for a total of seven days to assess the efficacy and safety of tolvaptan in the treatment of PAH-induced right heart failure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Within 12 hours of admission, traditional standard therapy (furosemide:20-40mg/d) is used for all subjects in our clinical trial. The treatment lasts for a total of seven days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Within 12 hours of admission, traditional standard therapy (furosemide:20-40mg/d) is used for all subjects in our clinical trial. The treatment lasts for a total of seven days.
Study: NCT05341167

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HPI algorithm using Edwards device https://www.edwards.com/gb/devices/decision-software/hpi
Description: The HPI algorithm will be used in order to prevent hypotensive episodes. When the HPI is greater than 85%, the anesthesiologist will have to intervene within the next 2 minutes taking the hemodynamic parameters available into consideration, as well as the treatment protocol that has been designed according to current literature
Study: NCT06496581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: ADT, abiraterone and each ARSI (Apalutamide, Darolutamide, Enzalutamide) will be administrated according to the standard of care
Study: NCT05230914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified imaging strategy
Description: NCCT and CTA will be used to screen patients for endovascular treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard imaging strategy
Description: NCCT-ASPECTS (pc-ASPECTS), CTA, and CTP will be used to screen patients for endovascular treatment
Study: NCT04869098

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein
Description: Protein drink containing 30g whey protein isolate powder (dissolved in water) consumed 1-1.5 hr prior to their main evening meal every day for 12 days, No other advice will be given.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Energy-matched mixed-nutrient placebo drink consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given.
Study: NCT06493461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS135
Description: HS135 is dosed subcutaneously
Study: NCT05139914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg/day (in capsule form) of dapagliflozin for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin
Description: 10 mg/day (in capsule form) of dapagliflozin for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule for 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule for 6 weeks
Study: NCT05341167

Intervention type: DRUG
Group type: OTHER
Intervention: Vasoactive Agent
Description: Hypotensive episodes will be treated with vasoactive agents and fluids. The HPI algorithm recordings will be blinded and will not be available to the anesthesiologist for the duration of the operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasoactive Agent
Description: Hypotensive episodes will be treated with vasoactive agents and fluids. The HPI algorithm recordings will be blinded and will not be available to the anesthesiologist for the duration of the operation.
Study: NCT05609968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT06202872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma (40 Hz) tACS at the precuneus region
Description: 40 Hz tACS applied at a current of 3.2 milliampere peak-to-peak using a NuroStym transcranial electrical stimulation (tES) system of NeuroDevice for four times 12 minutes (48 minutes in total) at the Pz (according to the 10-20 international EEG coordinates)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tACS at the precuneus region
Description: Sham tACS applied with no effective stimulation between the ramp-up and ramp-down of the current using a NuroStym tES system of NeuroDevice for four times 12 minutes (48 minutes in total) at the Pz (according to the 10-20 international EEG coordinates)
Study: NCT05192824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology lens
Description: The intervention was according to the design of different optical zone and peripheral reverse curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology lens
Description: The intervention was according to the design of different optical zone and peripheral reverse curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology lens
Description: The intervention was according to the design of different optical zone and peripheral reverse curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology lens
Description: The intervention was according to the design of different optical zone and peripheral reverse curve
Study: NCT04730180

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Simulation
Description: Brain stimulation treatment will be performed using FDA-cleared TMS coils according to their intended use of treatment of medication resistant depression by targeting the dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Simulation
Description: Brain stimulation treatment will be performed using FDA-cleared TMS coils according to their intended use of treatment of medication resistant depression by targeting the dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mixed reality neuronavigation
Description: Targeting of the dorsolateral prefrontal cortex will be performed with the help of a mixed reality neuronavigation system.
Study: NCT05135377

Intervention type: OTHER
Intervention: Observational
Description: Not applicable - observational study
Study: NCT04884594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV8-hCocH
Description: 2e12 vg/kg single infusion intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV8-hCocH
Description: 6e12 vg/kg single infusion intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV8-hCocH
Description: 4e12 vg/kg single infusion intravenous
Study: NCT06130969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Retraction Exercise
Description: Participants will hold cervical retraction for 10 s up to 10 times. A break of 5 s will be provided per one movement and 30 s per one set. A total of three sets will be conducted. Therefore, the total exercise time will be \<10 mints.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Retraction Exercise
Description: Participants will hold cervical retraction for 10 s up to 10 times. A break of 5 s will be provided per one movement and 30 s per one set. A total of three sets will be conducted. Therefore, the total exercise time will be \<10 mints.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing
Description: The diaphragmatic exercise will be performed in a supine position with 40° trunk flexion while holding 2.5 kg on the abdomen in the first 5 sessions and then 5 kg in the second 5 sessions. Participants will perform 3 sets with 10 repetitions at a ratio of one second of inspiration to two seconds of expiration, three sets of 15 repetitions at a ratio of two seconds of inspiration to four seconds of expiration, and three sets of 20 repetitions at a ratio of three seconds of inspiration to six seconds of expiration. The rest between rests will be 60 s.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline Treatment
Description: Hot fomentation will be given by applying cervical hot pack over the area in prone lying position for 10 mints and Isometric neck strengthening exercises (10 repetitions, each 5-second hold, 1 set) (20). • Nerve Stimulation (TENS) on the painful regions around the neck for 15 minutes with a TENS device. TENS parameters will be 150 μs square pulses with a frequency of 80 Hz.~The intensity of the current will be adjusted to produce no contraction.~• Posture education to keep upright posture during sitting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline Treatment
Description: Hot fomentation will be given by applying cervical hot pack over the area in prone lying position for 10 mints and Isometric neck strengthening exercises (10 repetitions, each 5-second hold, 1 set) (20). • Nerve Stimulation (TENS) on the painful regions around the neck for 15 minutes with a TENS device. TENS parameters will be 150 μs square pulses with a frequency of 80 Hz.~The intensity of the current will be adjusted to produce no contraction.~• Posture education to keep upright posture during sitting.